Prostate Cancer Coalition of New Hampshire

BREAKING NEWS: FDA Approves Apalutamide (Erleada) for the treatment of metastatic hormone-sensitive prostate cancer

September 18, 2019 By PCCNH

September 18, 2019 – Last night the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC). Apalutamide has previously received FDA-approval for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).

PCF funded the initial synthesis of apalutamide at UCLA by chemist Michael Jung, PhD, in collaboration with prostate cancer physician-scientist Charles Sawyers, MD (now at Memorial Sloan Kettering Cancer Center).

Read More

Filed Under: Events, News

  • Home
  • About
  • PCCNH Officers and Directors
  • Sponsors & Partners
  • FAQ
  • Resources
  • One Man’s Story: A Conversation About Living With Prostate Cancer
  • Support Groups
New Hampshire Prostate Cancer Coalition believes that information about products and services that could benefit people with prostate cancer should be made available to all consumers so they may make informed decisions. Any references to specific products, services, organizations or claims made in any advertisements or sponsorships of New Hampshire Prostate Cancer Coalition does not constitute an endorsement or recommendation of that product or service. New Hampshire Prostate Cancer Coalition strongly urges you to consult with a qualified medical doctor when considering all options concerning prostate cancer treatment.

Awareness - Education - Support - Research 

© 2023 Prostate Cancer Coalition of New Hampshire · Website Services by Orchid Sun